Article
Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.
Lung cancer (Amsterdam, Netherlands) - 1 Sept 2018
Suh Chong Hyun, Park Hye Sun, Kim Kyung Won, Pyo Junhee, Hatabu Hiroto, Nishino Mizuki
Abstract excerpt
PURPOSE: Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI) in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in clinical trials of EGFR-TKI published in 2003-2017, and performed subgroups analyses to identity predisposing factors. METHODS: Ovid-MEDLINE and EMBASE search up to 4/17/17 using the keywords, "erlotinib", "gefitinib", "afatinib",...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.